Pharma sector poised to grow at 9% till FY30: Care Ratings

THE INDIAN PHARMA sector remains largely insulated from the immediate effects of the 100% tariffs imposed by the US administration on branded and patented products imported into the country, according to a report from Care Ratings.

- MANU KAUSHIK

This is primarily due to the export of generic medicines to the US, which accounts for 90-95% of overall pharma shipments.

These generics are off-patent, low-cost alternatives and are not covered under the new tariff regime.

“India continues to play a critical role in supplying affordable medicines to the US, contributing nearly 45% of all generic prescriptions by volume. While the current tariff announcement does not impact Indian generics, the industry remains vigilant. Any future expansion of the tariff scope to include complex generics or biosimilars could pose challenges,’ the report said.